Company intelligence / Profile preview

Molecule 46

Ownership: Private
Development stage: Preclinical

Overview

Molecule 46’s technology has been validated through in-vitro benchmarking studies with endorsement from seven leading IVF clinics in the Czech Republic. The product is at MVP version 2.0 with strong proof-of-market and scientific evidence but has not yet entered clinical trials or commercial use.

Therapeutic areas: OtherOncologyWomen's HealthMen's Health
Modalities: Device-based separation technology for sperm selectionNot a therapeutic drug or biologic; rather, a patented device/process for cell selection
Industry: Therapeutic Medical Devices

Partnerships

Endorsement by seven leading IVF clinics in the Czech RepublicFinancial support from SIC and CzechInvest Technology Incubation programs

Beyond the preview

Go deeper on Molecule 46.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Molecule 46.

Explore the full profile